Abstract
Although patients with hormone-receptor-positive, HER2-negative, early breast cancers present with the best outcome among all breast cancer subtypes, about a third of patients will relapse at some point, even after receiving standard multimodal treatments. Efforts to improve survival in this population are ongoing, such as through the development of new endocrine agents or extended duration of endocrine treatment. Novel strategies are of considerable interest. CDK4/6 inhibition has been the most successful strategy in the treatment of hormone-receptor-positive, HER2-negative, advanced breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
